We share with you a useful leaflet created and translated to English by Colitis - Crohn Foreningen Denmark, our member in Denmark.
The brochure provides valuable insights into the most common intestinal diseases and offers guidance on what to avoid saying to someone with bowel problems.
EFCCA is actively engaged in seven large-scale EU-funded research projects under the Innovative Medicine Initiative and Horizon Europe programmes. EFCCA’s participation in these projects highlights our commitment to advancing research and addressing the unique needs and interests of patients with Inflammatory Bowel Disease (IBD).
Our latest issue of the EFCCA magazine is out!!!
You will find updates on our activities, news from our members and partners, experiences of living with IBD and ongoing medical research.
Happy reading!
Our latest issue of the EFCCA magazine is out!
You will find updates on our activities, news from our members and partners, experiences of living with IBD and ongoing medical research.
Happy reading!
August 2023
An international patient survey examined the impact of Crohn’s perianal fistula on patients' quality of life. Patients with both Crohn’s disease and perianal fistulae reported significantly greater negative effects on overall quality of life, well-being, relationships, social life, and work life compared to those with only Crohn’s disease. The study highlights the need for targeted therapeutic strategies to address these burdens.
Our latest issue of the EFCCA magazine is out!!!
You will find updates on our activities, news from our members and partners, experiences of living with IBD and ongoing medical research.
Happy reading!
EFCCA´s new working methodology aims to identify and address the real needs of patients with Crohn’s disease and Ulcerative Colitis, also collectively known as Inflammatory Bowel Disease (IBD).
The working methodology is based on the concept of analysing and interpreting scientific data in order to improve therapeutic outcomes. EFCCA’s approach is called DIVA (Data Insights for Added therapeutic VAlue) which will make use of publicly available data as well as internal EFCCA data to analyse and interpret the IBD patient communities’ unmet needs.
EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD.
November, 2022
The study developed a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Other indicators include, for example, clinical, endoscopic, and biomarker remission, fatigue, and urgency to go to the toilet.